This is a working overview of anxiolytic, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
== Structure == IDH1 is one of three isocitrate dehydrogenase isozymes, the other two being IDH2 and IDH3, and encoded by one of five isocitrate dehydrogenase genes, which are IDH1, IDH2, IDH3A, IDH3B, and IDH3G. IDH1 forms an asymmetric homodimer in the cytoplasm and carries out its function through two hydrophilic active sites formed by both protein subunits. Each subunit or monomer is composed of three domains: a large domain (residues 1–103 and 286–414), a small domain (residues 104–136 and 186–285), and a clasp domain (residues 137 to 185). The large domain contains a Rossmann fold, while the small domain forms an α/β sandwich structure, and the clasp domain folds as two stacked double-stranded anti-parallel β-sheets. A β-sheet joins the large and small domains and is flanked by two clefts on opposite sides. The deep cleft, also known as the active site, is formed by the large and small domains of one subunit and a small domain of the other subunit. This active site includes the NADP-binding site and the isocitrate-metal ion-binding site. The shallow cleft, also referred to as the back cleft, is formed by both domains of one subunit and participates in the conformational changes of homodimeric IDH1. Finally, the clasp domains of both subunits intertwine to form a double layer of four-stranded anti-parallel β-sheets linking together the two subunits and the two active sites. Furthermore, conformational changes to the subunits and a conserved structure at the active site affect the activity of the enzyme.
==== Nuclear power ==== There were three nuclear power plants in Schleswig-Holstein: Krümmel, Brunsbüttel, and Brokdorf. The last operating plant in Schleswig-Holstein, the Brokdorf-plant was shut down on new-years eve 2021. There is also a nuclear research center known "Helmholtz-Zentrum Geesthacht" (rebranded as Hereon) with 2 research reactors, located right next to the Krümmel plant. During the 1990s, ten more cases of leukemia among children than were expected were identified in Elbmarsch, near the Krümmel plant. Anti-nuclear activists believed it was due to the nuclear plant, which led to several investigations. The reported discovery of small spherical beads of nuclear material in the area led to further concern, as well as the presence of minute amounts of plutonium in the Elbe. The origins of the nuclear material were disputed, with one report determining them not to be that of the Krümmel plant. Another report claimed that they may have come from an undisclosed fire in 1986, however, this theory has been questioned as it would have required a substantial government cover-up. The Chernobyl disaster has also been suggested as a source, though it is considered unlikely. The probable source of the material, especially in the Elbe, is nuclear reprocessing plants in France. A 2010 report exonerated the nuclear power plants on the Elbe as the cause of contamination. Further doubt was cast on the nature of the supposed beads of nuclear material, with a Federal commission chastising the original commission that claimed to have discovered the beads.
=== Portion size irregularities === Some customers took to the social media platform TikTok accusing Chipotle of reducing portion sizes. In June 2024, a Wells Fargo analyst and his team set investigated the matter and ordered 75 identically configured items from 8 different Chipotle locations in New York City. The team weighed each bowl and reported that portion sizes varied widely, ranging from 14 to 27 ounces (400 to 770 g) with a median weight of 21.5 ounces (610 g).
In published reports by other authors, 2C-B has been claimed to produce effects including visual, auditory, and tactile perceptual changes, closed-eye imagery, LSD-like visuals such as colors and geometric shapes, time dilation, MDMA-like stimulant and entactogenic effects, such as being more in touch with emotions, as well as feelings of love, enhanced sociability, and empathy, feelings of peace and well-being, euphoria, a "body high", increased sensitivity to touch, touch feeling pleasurable, and being erotic. The presence of entactogenic effects with 2C-B is said to be unique among most psychedelics, along with certain other atypical psychedelics like 5-MeO-DiPT and 5-MeO-MiPT. 2C-B's effects are often described as being milder and more easily managed than other psychedelics. For example, it is said to be less incapacitating or impairing, "non-ego-threatening", not "mentally challenging" or confusing, not leading to an "extreme headspace", and leaving the mind "very clear". In addition, it is said to produce changes in thought and time perception less frequently. Due to its potential for relatively light effects, the drug has been referred to as the "Diet Coke of psychedelics" or as a "beginner psychedelic". Nonetheless, it has been described as quite visual, with the potential for all of the visuals of LSD but without the head space that LSD and psilocybin produce. However, the visuals are dose-dependent, being mild at lower doses and being more substantial and LSD-like at higher doses. 2C-B is often compared to a mixture of LSD and MDMA or a "candyflip".
== Research == Filorexant was studied for but was not found to be effective in the treatment of diabetic neuropathy, migraine, and major depressive disorder in phase 2 clinical trials. Seltorexant is under development for treatment of major depressive disorder however and is in phase 3 trials for this indication. Also, suvorexant is in a phase 4 trial for use as an adjunct to antidepressant therapy in people with major depressive disorder and residual insomnia.
Sources: en.wikipedia.org
== Function == Urocortin (UCN) II, also known as stresscopin-related peptide, is a 38 amino acid member of the mammalian corticotropin-releasing hormone (CRH) peptide family, which also includes CRH, UCN I, and UCN III. CRH mainly binds to type 1 CRH receptors (CRH1), while UCN II and III bind primarily to type 2 CRH receptors, and UCN I binds to both (CRH2). Each of these hormones has distinctive distribution patterns in the central nervous system and the periphery, suggesting each peptide may have distinct behavioral and physiological effects, although all have been associated with anxiety. In general, agonism of CRH1 receptors is posited to be anxiogenic and agonism of CRH2 receptors is posited to be anxiolytic. Urocortin II has been shown to have anorexigenic effects and hypotensive effects similar to Urocortin, but does not induce secretion of ACTH.
=== L’Art islamique en Orient I, II and III (Islamic Art in the East I, II and III) === In 1922, he worked on publishing the first book of his Islamic art reproductions, Alttürkishe Keramik or L’Art islamique en Orient – Première Partie (Islamic Art in the East – Part One, published in French). In 1923, with the financial backing of American millionaire Charles Crane, he commissioned the printing of L’Art islamique en Orient, Deuxième Partie (Fragments d’architecture religieuse et civile) (Islamic Art in the East, Part Two (Fragments of Religious and Civil Architecture)) and L’Art islamique en Orient, Troisième Partie (Islamic Art in the East, Part Three), published in French in Prague by the Printing House Schulz.
The territorial authorities of New Zealand are the country's municipal local government entities, existing alongside the country's regional councils. There are 67 such authorities, including 12 city councils, 53 district councils and 2 sui generis councils (Auckland Council and Chatham Islands Council). Five territorial authorities also have the powers of regional councils, and these are called unitary authorities. Territorial authorities are not subservient to regional councils, and several of them have jurisdictions overlapping multiple regional council areas. Territorial authorities are responsible for the administration of local matters and resources. These include roads, building consents, water supply and sanitation, amongst other responsibilities. Non-unitary territorial authorities are not responsible for broader regional environmental management or public transport, as those are the responsibilities of the regional councils.
captions: A) The cetaceum (podium of cetaceans), in the Comparative Anatomy gallery B) Statue of Bernardin de Saint-Pierre, with Paul and Virginia C) The alpine garden D) The Hôtel de Magny E) The gallery of Palaeontology and Comparative Anatomy, with the statue of the First Artist by Paul Richer F) The Gallery of Mineralogy and Geology G) The greenhouse of New Caledonia built between 1834 and 1836 (at the time the "oriental pavilion") according to the plans of Charles Rohault de Fleury H) Cuvier's house on the left and the triangular pediment of the east wing of the Whale Pavilion on the right I) The Becquerel alley, north side, leads to Cuvier's house where Henri Becquerel discovered radioactivity in 1896 J) The Palaeontology gallery, on the second floor, with its mezzanine. The second floor exhibits the vertebrate fossils and the mezzanine the invertebrate fossils K) One of the zoological shelters of the menagerie L The façade of the Musée de l'Homme, in the southwest wing of the Palais de Chaillot M The botanical museum of La Jaÿsinia, in the Alps N The excavations of the Pataud shelter, in Dordogne.
Bio-Synthesis, Inc. (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.